​

Liquidia Stock (NASDAQ:LQDA)

ForecastRevenueOwnershipFinancialsChartTranscripts
Liquidia by TradingView

Previous Close

$38.56

52W Range

$11.26 - $46.67

50D Avg

$37.15

200D Avg

$26.68

Market Cap

$3.27B

Avg Vol (3M)

$1.87M

Beta

0.56

Div Yield

-

LQDA Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

170

IPO Date

Jul 26, 2018

Website

LQDA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 20
Service$10.03M-
Product$148.29M-
Promotion Agreement-$739.63K
Research and Development Services--

Fiscal year ends in Dec 25 | Currency in USD

LQDA Financial Summary

Dec 25Dec 24Dec 23
Revenue$158.32M$14.00M$17.49M
Operating Income$-51.38M$-121.29M$-73.38M
Net Income$-68.92M$-130.39M$-78.50M
EBITDA$-51.38M$-115.71M$-70.05M
Basic EPS$-0.80$-1.66$-1.21
Diluted EPS$-0.80$-1.66$-1.21

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 05, 26 | 8:30 AM
Q3 25Nov 03, 25 | 8:30 AM
Q2 25Aug 12, 25 | 12:30 AM

Peer Comparison

TickerCompany
GLPGGalapagos N.V.
OCULOcular Therapeutix, Inc.
RCUSArcus Biosciences, Inc.
DNLIDenali Therapeutics Inc.
MESOMesoblast Limited
IBRXImmunityBio, Inc.
COGTCogent Biosciences, Inc.
AGIOAgios Pharmaceuticals, Inc.
GPCRStructure Therapeutics Inc.